Varian Medical Systems Inc. completed the acquisition of Boston Scientific Corp.'s surgical bead products, which were placed on the market at the request of the U.S. Federal Trade Commission.
The FTC flagged the drug-eluting beads as an area of overlap in Marlborough, Mass.-based Boston Scientific's planned $4.2 billion acquisition of London's BTG International Ltd.
Palo Alto, Calif.-based Varian picked up the products, which include drug-loadable microsphere and bland embolic beads that treat arteriovenous malformations, an abnormal tangle of blood vessels, and hypervascular tumors, which attach to blood vessels.
Financial terms of the portfolio acquisition were not disclosed in an Aug. 21 news release.
Boston Scientific closed the BTG deal Aug. 19.
